Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. - Cohen G; Rapoport B; Chan SW; Ruff P; Arance A; Mujika Eizmendi K; Houghton B; Brown MP; Zielinski RM; Muñoz Couselo E; Lyle M; Anderson JR; et al. (PloS one, 2024)